Инвестор Эндрю Хиллман поддержал образовательный портал FixCancers.com, посвященный биологии рака и клиническим исследованиям

DALLAS, TEXAS — Andrew Hillman, a Dallas-based investor, entrepreneur, and business strategist with more than 30 years of experience in business growth and investment, today announced his support for FixCancers.com, an independent educational and awareness companion site to FixCancer.org. The site is designed to give patients, families, and caregivers plain-language information about advanced cancer biology and the investigational research being conducted in the field. FixCancers.com covers the fundamentals of advanced (Stage 3 and Stage 4) cancer, including how staging works, the categories of standard cancer treatment, and how clinical trials are structured and regulated. Sourced in part from organizations such as the National Cancer Institute, the site is built to help readers ask better-informed questions of their own oncologists rather than to direct, recommend, or arrange care. The site also provides an awareness-level summary of one area of published research: Targeted Osmotic Lysis (TOL), a research-stage approach being studied in solid tumors that overexpress voltage-gated sodium channels. FixCancers.com is explicit that TOL is investigational and not FDA-approved, that there are no published randomized human trials and none currently registered on ClinicalTrials.gov, and that the human evidence to date is limited to a single emergency-use case report. The site does not offer, sell, or arrange treatment of any kind, does not assess patient eligibility, and is not a substitute for medical advice. "Most people facing an advanced cancer diagnosis are handed a wall of clinical language at the exact moment they're least equipped to process it," said Andrew Hillman. "My interest here isn't medical — it's making sure people have an accurate, honest starting point for the conversations they need to have with their own oncologist. That means being clear about what the research actually shows, and just as clear about what it doesn't show yet." Hillman's involvement with FixCancers.com reflects his broader focus on biotechnology and the intersection of business strategy, investment, and emerging science. Over his career, he has founded multiple ventures and worked to identify, fund, and scale companies across a range of industries, while also serving as a senior paralegal at a private law firm specializing in financial strategy and compliance. He holds a background in Business Administration and Management from the SMU Cox School of Business and Dallas College. FixCancers.com will continue to expand its library of educational explainers on cancer biology, treatment evaluation, and how to read clinical evidence, with all content reviewed for accuracy against primary sources such as peer-reviewed publications and the National Cancer Institute. About Andrew Hillman Andrew Hillman is a Dallas, Texas-based investor, entrepreneur, and business strategist with over 30 years of experience driving company growth, optimizing operations, and identifying high-potential investment opportunities. He is the founder of multiple ventures and serves as a senior paralegal at a private law firm, specializing in financial strategy and compliance. He holds a background in Business Administration and Management from the SMU Cox School of Business and Dallas College. His professional interests center on biotechnology, startup investment, and the legal and financial strategies that help companies scale. About FixCancers.com FixCancers.com is an independent educational and awareness companion to FixCancer.org. It provides plain-language public education on advanced solid tumor cancer biology, staging, treatment categories, and clinical trial structure. The site does not offer, recommend, sell, or arrange treatment, and does not assess patient eligibility for any therapy. Information on the site is educational only and is not medical advice; readers are directed to discuss any treatment decisions with their own licensed oncologist. FixCancers.com is an educational resource and is not a substitute for professional medical advice, diagnosis, or treatment. The therapies referenced, including Targeted Osmotic Lysis, are investigational and have not been approved by the U.S. Food and Drug Administration.